Neurotechnology
Neuralink
30-Second Executive Brief
Executive Assessment
Neuralink functions as an established institution within Neurotechnology, backed by 43% sourcing coverage, with a stable competitive position.
- Maintains 4 mapped relationships across the graph
- 43% sourcing coverage across sourced relationships
- Tracked as established institution within the Neurotechnology category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 43%
- Ecosystem Influence
- High
- Strategic Momentum
- Steady
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 4
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Elon Musk's brain-computer interface company implanting its N1 device via the R1 surgical robot, running the PRIME trial (quadriplegia/ALS patients controlling computers and robotic arms via thought) and the VOICE trial (decoding speech from thought). Neuralink reached its 26th human trial participant in 2026, up from 21 in January, after expanding trials to the UAE, UK and Canada, and raised a $650 million Series E in April 2026 at a roughly $9 billion valuation, bringing total funding to about $1.85 billion since founding.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
3 sources
- Basenor / MobiHealthNews — Neuralink reaches 26th patient in ongoing brain-computer interface trialsnews
- Interesting Engineering / Fierce Biotech — Neuralink advances Blindsight vision implant, hires former FDA executivenews
- Sacra / Tracxn — Neuralink raises $650M Series E at ~$9B valuationresearch
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Neuralink — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Bloomberg reported secondary-market share sales implying an $8.5 billion valuation
40% confidenceBloomberg reported that Neuralink insider share sales on secondary markets implied a valuation near $8.5 billion, ahead of the company's confirmed $9 billion pre-money Series E — with some later secondary trades reportedly implying materially higher figures.
Reported by Bloomberg News; secondary-market pricing is not an official company valuation and can diverge significantly from primary round terms.
Neuralink's Timeline
A sourced, dated history of Neuralink's key moments — founding to present.
Jan 2026 · First Canadian ALS patient implanted; targets high-volume production
Neuralink implanted its first Canadian patient (an ALS patient) under the four-year CAN-PRIME clinical trial at UHN Toronto Western Hospital, evaluating the N1 implant and R1 surgical robot for Canadian residents with cervical spinal cord injury or ALS; separately, Elon Musk announced plans to begin high-volume production of Neuralink's brain-computer interface devices in 2026 alongside a shift toward an almost entirely automated surgical implantation procedure.
Apr 2026 · $650M Series E at ~$9B valuation
Neuralink raised a $650 million Series E round in April 2026 at a roughly $9 billion valuation, bringing total funding to approximately $1.85 billion since founding.
Aug 2026 · Advances from cursor control to powered-wheelchair trials
Neuralink began testing thought-controlled powered wheelchairs with paralyzed trial participants, a materially harder real-world independence test than its earlier cursor-control demonstrations, while continuing parallel work on computer, smartphone, robotic-arm and communication control; the R1 surgical robot's single-thread insertion time reached 1.5 seconds at insertion depths exceeding 50mm, accommodating an estimated 99% of human brain anatomical variation.